Wire Stories
Zai Lab Announces Inclusion of ZEJULA� (Niraparib) in China�s National Reimbursement Drug List for First-Line Ovarian Cancer
SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative,...